Sven Zukunft
Dresden, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.
Journal: British journal of haematology
Published: March 04, 2026
Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: September 01, 2025
Urea cycle modulation by combined SGLT2 inhibitors and metformin.
Journal: BMC medicine
Published: July 18, 2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
Journal: American journal of hematology
Published: June 25, 2025
Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer.
Journal: Signal transduction and targeted therapy
Published: April 03, 2025
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
Journal: American journal of hematology
Published: July 16, 2024
IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition.
Journal: Cell metabolism
Published: April 16, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.
Journal: Blood advances
Published: March 05, 2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Journal: British journal of haematology
Published: February 09, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Journal: Haematologica
Published: February 06, 2024
Last Updated: 09/26/2026